Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy

Interleukin-2 (IL-2) therapy has been demonstrated to induce responses in 10-20% of advanced melanoma and renal cell carcinoma patients, which translates into durable remissions in up to half of the responsers. Unfortunately the use of IL-2 has been associated with severe toxicity and death. It has...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Samuel C, Markosian, Boris, Ajili, Naseem, Dolan, Brandon R, Kim, Andy J, Alexandrescu, Doru T, Dasanu, Constantin A, Minev, Boris, Koropatnick, James, Marincola, Francesco M, Riordan, Neil H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028098/
https://www.ncbi.nlm.nih.gov/pubmed/24884532
http://dx.doi.org/10.1186/1479-5876-12-127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028098/
https://www.ncbi.nlm.nih.gov/pubmed/24884532
http://dx.doi.org/10.1186/1479-5876-12-127

Ejemplares similares